Immunic Inc. Banner Image

Immunic Inc.

  • Ticker IMUX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Immunic Inc. Logo Image
  • 51-200 Employees
  • Based in New York City, New York
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), currently in phase 3 clinical trials for the treatment of multiple sclerosis and which has shown therapeutic activity in phase 2 clinicalMore trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis, selectively inhibits activated immune cells and shows combined anti-inflammatory, anti-viral and neuroprotective effects. IMU-856 is targeted to restore intestinal barrier function and regenerate bowel epithelium, which would be applicable in numerous gastrointestinal diseases, such as celiac disease, where it is currently in preparations for a phase 2 clinical trial.
4.8 / 5.0 (141)

Immunic Inc. reports have an aggregate usefulness score of 4.8 based on 141 reviews.

Immunic Inc.

Most Recent Annual Report

Immunic Inc.
MOST RECENT 2023 Annual Report and Form 10K

Immunic Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

Immunic Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!